Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 307

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 1A
Chunk 307
---
 paid to contract manufacturing organizations, including the cost of acquiring, developing, and manufacturing research material; costs associated with clinical activities, including expenses for contract research organizations; and clinical trials and activities related to regulatory filings for our product candidates, including regulatory consultants.

			●

			General and administrative (“G&A”) expenses increased by $0.1 million to $4.2 million for the year ended September 30, 2025 compared to $4.1 million for the prior year primarily due to an increase in noncash share-based compensation, which was partially offset by a decrease in professional fees. Our G&A expenses consist primarily of salaries and related costs for our employees in administrative, executive and finance functions. G&A expenses also include professional fees for legal, accounting, audit, tax and consulting services, insurance, office, and travel expenses.

44

Total other income decreased by $0.1 million to $0.7 million for the year ended September 30, 2025 compared to $0.8 million for the prior year, and was composed of the following:

			●

			Grant income increased by $0.1 million to $0.8 million for the year ended September 30, 2025 compared to $0.7 million for the year ended September 30, 2024, reflecting an increase in grant income associated with reimbursable expenses under the 2023 SIF Agreement.

			●

			Interest income decreased to $3,000 for the year ended September 30, 2025 from $0.2 million for the prior year, primarily due to lower interest earned on cash balances.

			●

			No miscellaneous other income was recorded in the year ended September 30, 2025 compared to $15,000 in the year ended September 30, 2024 related to loan forgiveness on the Canada Emergency Business Account (“CEBA”) loan that was repaid during the year.

			●

			Foreign exchange loss increased to $59,000 in the year ended September 30, 2025 compared to $21,000 in the year ended September 30, 2024.

For the year ended September 30, 2025, our net loss was $7.2 million, or $1.27 per common share, compared to a net loss of $6.2 million, or $1.93 per common share, for the year ended September 30, 2024.

Capital Ex